Core Viewpoint - The recent price adjustment notification from the Shanghai Sunshine Pharmaceutical Procurement Network has caused significant industry impact, with the second price drop for two major traditional Chinese medicine injections, indicating a strong signal for price control in the industry [1][2]. Group 1: Price Adjustments - The injection price of Shuanghuanglian (600mg) produced by Heilongjiang Songhua River Pharmaceutical Technology Co., has decreased from 19.7 yuan to 12.45 yuan, a reduction of over 36% [1]. - The price of Honghua injection (20ml) from Yabao Pharmaceutical Group has dropped from 74.98 yuan to 50.64 yuan, a decrease of over 32% [1]. - The average price reduction across 174 selected drugs in the third batch of national traditional Chinese medicine procurement reached 68%, marking a record high [2]. Group 2: Industry Context - The third batch of national traditional Chinese medicine procurement began in December 2024, led by the Hubei Provincial Medical Insurance Bureau, involving 95 generic products and 400+ companies [2]. - The price of Qingkailing injection (2ml) from Shanxi Taihang Pharmaceutical dropped by 93.8%, from 16.08 yuan to 0.99 yuan, setting a new price benchmark [2]. - The price adjustment reflects the urgent need for price balance in traditional Chinese medicine, as the industry has long faced issues of inflated prices and significant price differences among similar products [8]. Group 3: Regulatory and Market Implications - The price adjustments are part of a broader effort to address the price disparity issues that have emerged during the procurement process, which have hindered the effectiveness of price reductions [9]. - Starting from April 2025, the results of the third batch of traditional Chinese medicine procurement will be implemented nationwide, with 25 provinces already confirming execution dates [8]. - The Hubei Province plans to initiate the fourth batch of traditional Chinese medicine procurement this year, aiming to further optimize pricing calculation methods and quality standards [9].

Group 1 - The core point of the announcement is that the company, Yabao Pharmaceutical Group Co., Ltd., is transferring part of its equity in Wuhan Jianmin Capital Partnership to its wholly-owned subsidiary, Yabao Ailegao, and is also withdrawing from the partnership to optimize external investments and improve asset operation efficiency [1][7]. Group 2 - The company signed an equity transfer agreement with Zhejiang Huafang Asset Management Co., Ltd., acquiring a 40.68% stake in Wuhan Jianmin Capital with a subscribed capital of 120 million RMB, while the actual paid-in capital was 0 RMB [1]. - After a capital reduction, the total capital contribution of all partners in Jianmin Capital was 274.58 million RMB, with the company holding a 43.70% stake [2]. - The company transferred 5 million shares of Jianmin Capital for 49.0235 million RMB to Yabao Ailegao and withdrew from 7 million shares for 68.633 million RMB [2][5]. Group 3 - The total capital contribution of Jianmin Capital after the transfer and withdrawal will be reduced to 204.58 million RMB, with Yabao Ailegao holding a 24.44% stake [6]. - The net asset value of Jianmin Capital as of December 31, 2024, was reported at 253.7888 million RMB [5]. Group 4 - The purpose of this transaction is to optimize external investments and recover funds, which will enhance the company's asset operation efficiency without adversely affecting its normal production and financial status [7].

证券代码：600351 证券简称：亚宝药业 公告编号：2025-026 亚宝药业集团股份有限公司 关于合伙企业份额转让给全资子公司暨退伙的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、投资合伙企业情况概述 1、2020年12月18日，亚宝药业集团股份有限公司（以下简称"公司"或"亚 宝药业"）与浙江华方资产管理有限公司（以下简称"华方资产"）签署了《武 汉健民资本合伙企业（有限合伙）合伙权益转让协议》，公司以0元人民币受让 华方资产持有的武汉健民资本合伙企业（有限合伙）（以下简称"健民资本"） 40.68%的财产份额。健民资本全体合伙人认缴出资总额为29,500万元，其中：华 方资产认缴出资13,350万元，实缴出资0元。转让完成后，公司成为健民资本新 的有限合伙人，持有健民资本40.68%的份额，对应认缴出资额12,000万元。具体 内容详见公司于2020年12月19日在上海证券交易所、上海证券报及中国证券报上 披露的《亚宝药业集团股份有限公司关于受让武汉健民资本合伙企业（有限合伙） 财产份额的公告》（公告编号： ...

Core Viewpoint - The company is optimizing its external investments and improving asset operation efficiency through the transfer of its stake in Wuhan Jianmin Capital Partnership [1] Group 1 - The company announced the transfer of its 50 million yuan stake in Wuhan Jianmin Capital Partnership for 49.0235 million yuan to its wholly-owned subsidiary, Yabao Ailegao Biopharmaceutical Co., Ltd [1] - The company agreed to withdraw from a 70 million yuan stake for 68.633 million yuan [1] - After the transaction, the total capital contribution of all partners in Jianmin Capital will decrease to 205 million yuan, and the company will hold a 24.44% stake in Jianmin Capital through its subsidiary [1]

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

Group 1 - The company has approved a share repurchase plan with a total funding amount between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 6.95 per share [1][2] - The repurchase will be conducted through centralized bidding and aims to cancel the repurchased shares, thereby reducing the registered capital of the company [1] - The repurchase period is set for a maximum of 6 months from the date of the shareholders' meeting approval [1] Group 2 - The company has obtained a loan commitment letter from the Bank of China, with a maximum loan amount of RMB 90 million and a loan term not exceeding 3 years [2] - The loan is intended to support the company's share repurchase activities [2] - The actual repurchase amount will be determined based on the market conditions and the availability of funds at the end of the repurchase period [2]

亚宝药业集团股份有限公司 关于取得金融机构股票回购贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回购股份方案的基本情况 亚宝药业集团股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 了 2024 年年度股东大会，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司以集中竞价方式回购公司股份，回购股份的资金总额不低于 人民币 0.5 亿元（含）且不超过人民币 1 亿元（含），回购股份价格不超过人民 币 6.95 元/股，回购用途为全部予以注销并减少公司注册资本，回购期限为自股 东大会审议通过回购方案之日起不超过 6 个月，本次回购资金来源为公司自有资 金及自筹资金。具体内容详见公司于 2025 年 5 月 17 日在上海证券交易所网站 （www.sse.com.cn）及《中国证券报》《上海证券报》上发布的《亚宝药业集团 股份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号： 2025-020）。 二、取得金融机构股票回购贷款承诺函的情况 近日，公司取得中国 ...

亚宝药业（600351）公告，公司近日取得中国银行股份有限公司运城市分行出具的《贷款承诺函》，承 诺贷款金额最高不超过9000万元，贷款期限不超过3年，贷款用途为股票回购。此前，公司于2025年5月 16日召开的2024年年度股东大会审议通过了以集中竞价方式回购股份的议案，回购资金总额不低于0.5 亿元且不超过1亿元，回购价格不超过6.95元/股，回购用途为全部予以注销并减少公司注册资本，回购 期限为不超过6个月，资金来源为公司自有资金及自筹资金。 ...

Core Viewpoint - The announcement from the Shanxi Provincial Drug Administration details the results of GMP compliance inspections for 14 pharmaceutical manufacturing companies, indicating their adherence to national drug production standards [2]. Group 1: Inspection Results - The inspection results include companies such as China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., which was inspected for hard capsule production of penicillin oral preparations [3]. - Other companies listed include Shanxi Huida Pharmaceutical Co., Ltd. and Shanxi Zhongyuan Pharmaceutical Co., Ltd., with various products ranging from oral solutions to traditional Chinese medicine pieces being evaluated for compliance [3][4]. - The inspections were conducted between January 16 and March 31, 2025, with all companies listed achieving compliance [3][4]. Group 2: Compliance Details - The compliance checks were based on the Drug Administration Law of the People's Republic of China and related regulations, ensuring that the inspected companies meet the required quality management standards [2]. - Specific products inspected include oral solutions, hard capsules, and raw materials, with detailed addresses and production lines provided for each company [3][4]. - The results signify a commitment to maintaining high standards in pharmaceutical production within the region, which is crucial for public health and safety [2].

Group 1 - The company will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 9, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted via video live streaming and online interaction at the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions from May 30, 2025, to June 6, 2025, through the Roadshow Center website or via the company's email [3] Group 2 - Key personnel attending the briefing include the Chairman, Secretary of the Board, Chief Financial Officer, and an Independent Director [2] - After the briefing, investors can view the main content and details of the event on the Shanghai Stock Exchange Roadshow Center [3]